A. Weil

Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke

C. Edenius, O. Borgå, T. Odergren, 2002, European Journal of Clinical Pharmacology.

Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial

I. Langbakke, T. Klitgaard, M. Lange, 2007, Clinical endocrinology.

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

Paul D. Martin, S. Oliver, P. Langmuir, 2010, Clinical pharmacokinetics.

The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.

G. Layton, Keith Tan, S. Sobue, 2004, British journal of clinical pharmacology.

Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation.

A. Weil, C. Maillot, R. Sauron, 2006, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole

O. Borgå, A. Couturier, T. Odergren, 2003, European Journal of Clinical Pharmacology.

1238 An open-label study of the pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe renal impairment, or normal renal function

H. Tomkinson, S. Oliver, H. Swaisland, 2009 .

Effect of gallbladder contraction induced cholagogia on the pharmacokinetic profile of a sustained-release theophylline formulation.

S. Gay, A. Laicher, W. Fuchs, 1996, Arzneimittel-Forschung.

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

Paul D. Martin, S. Oliver, P. Langmuir, 2010, Clinical pharmacokinetics.